Prostate cancer (PC) is a major health concern for men worldwide, with an estimated lifetime risk of ~14 %. A recent comprehensive analysis of mutational processes revealed ageing and mismatch repair as the only altered processes in PC. We wish to test if a cohort of men with inherited risk of mismatch repair defect through BRCA1/2 or Lynch Syndrome mutations represents a target population for prostate cancer testing.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Fifty-eight men (aged 40-69 years) from families with a history of BRCA1/2 or HNPCC/Lynch mutations were invited to take part. Men with PSA >3.0 ng/ml were recommended to have transrectal ultrasound-guided prostatic biopsies.
Overall 1 of 7 (14 %) and 1 of 20 (5 %) men with BRCA1/2 mutations were positive for a diagnosis of prostate cancer. In men with Lynch syndrome, 1 of 4 (25 %) was diagnosed to have prostate cancer. The index case with Lynch syndrome harbours a heterozygous mutation in the mismatch repair MSH6 gene. Near to complete loss of MSH6 immunoreactivity in the prostate tumour supports silencing of the remaining MSH6 allele during prostate carcinogenesis.
The finding of near-to-complete loss of MSH6 expression in affected men with a family history of Lynch Syndrome supports its mechanistic involvement during prostate carcinogenesis. This work therefore contributes to the argument that, in certain male populations, Lynch Syndrome mutations are biologically implicated in men with prostate cancer.
BMC cancer. 2016 Jul 25*** epublish ***
Lynne Kerr, Matthew J Rewhorn, Mark Longmuir, Sioban Fraser, Shaun Walsh, Nicola Andrew, Hing Y Leung
Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, G51 4TF, UK., Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, G51 4TF, UK., West of Scotland Genetic Service, Queen Elizabeth University Hospital, NHS Great Glasgow and Clyde, Glasgow, G51 4TF, UK., Department of Pathology, Queen Elizabeth University Hospital, NHS Great Glasgow and Clyde, Glasgow, G51 4TF, UK., Department of Pathology, Ninewells Hospital, Dundee, DD1 9SY, UK., Human Genetics Unit, Ninewells Hospital, Dundee, DD1 9SY, UK., Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, G51 4TF, UK. .